|
"hsu ta"的相關文件
顯示項目 1-25 / 83 (共4頁)
1 2 3 4 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2023-02-07 |
Development of furanopyrimidine-based orally active third- generation EGFR inhibitors for the treatment of non-small cell lung cancer
|
Li, MC;Coumar, MS;Lin, SY;Lin, YS;Huang, GL;Chen, CH;Lien, TW;Wu, YW;Chen, YT;Chen, CP;Huang, YC;Yeh, KC;Yang, CM;Kalita, B;Pan, SL;Hsu, TA;Yeh, TK;Chen, CT;Hsieh, HP |
| 國家衛生研究院 |
2022-09-26 |
Targeting the phosphatidylserine-immune checkpoint with a small-molecule maytansinoid conjugate
|
Lo, CF;Chiu, TY;Liu, YT;Pan, PY;Liu, KL;Hsu, CY;Fang, MY;Huang, YC;Yeh, TK;Hsu, TA;Chen, CT;Huang, LR;Tsou, LK |
| 國家衛生研究院 |
2022-06-21 |
Synthesis and evaluation of small molecule drug conjugates harnessing thioester-linked maytansinoids
|
Lo, CF;Chiu, TY;Liu, YT;Huang, LR;Yeh, TK;Huang, KH;Liu, KL;Hsu, CY;Fang, MY;Huang, YC;Hsu, TA;Chen, CT;Tsou, LK |
| 國家衛生研究院 |
2022-02-07 |
Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer
|
Li, MC;Coumar, MS;Lin, SY;Lin, YS;Huang, GL;Chen, CH;Lien, TW;Wu, YW;Chen, YT;Chen, CP;Huang, YC;Yeh, KC;Yang, CM;Kalita, B;Pan, SL;Hsu, TA;Yeh, TK;Chen, CT;Hsieh, HP |
| 國家衛生研究院 |
2022-01-18 |
Acyl-coenzyme a synthetase long-chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis
|
Kung, YA;Chiang, HJ;Li, ML;Gong, YN;Chiu, HP;Hung, CT;Huang, PN;Huang, SY;Wang, PY;Hsu, TA;Brewer, G;Shih, SR |
| 國家衛生研究院 |
2021-07-16 |
Colloidal assemblies composed of polymeric micellar/emulsified systems integrate cancer therapy combining a tumor-associated antigen vaccine and chemotherapeutic regimens
|
Huang, CY;Lin, SY;Hsu, TA;Hsieh, HP;Huang, MH |
| 國家衛生研究院 |
2020-05-23 |
Repurposing old drugs as antiviral agents for coronaviruses
|
Yang, CW;Peng, TT;Hsu, HY;Lee, YZ;Wu, SH;Lin, WH;Ke, YY;Hsu, TA;Yeh, TK;Huang, WZ;Lin, JH;Sytwu, HK;Chen, CT;Lee, SJ |
| 國家衛生研究院 |
2020-05-15 |
Artificial intelligence approach fighting COVID-19 with repurposing drugs
|
Ke, YY;Peng, TT;Yeh, TK;Huang, WZ;Chang, SE;Wu, SH;Hung, HC;Hsu, TA;Lee, SJ;Song, JS;Lin, WH;Chiang, TJ;Lin, JH;Sytwu, HK;Chen, CT |
| 國家衛生研究院 |
2019-12-17 |
Endothelial-mesenchymal transition harnesses HSP90alpha-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma
|
Fan, CS;Chen, LL;Hsu, TA;Chen, CC;Chua, KV;Li, CP;Huang, TS |
| 國家衛生研究院 |
2019-10 |
Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer
|
Hsieh, HP;Chang, JY;Yeh, CT;Lin, SY;Ke, YY;Lin, WH;Hsu, TA;Wu, SY;Yeh, TK |
| 國家衛生研究院 |
2019-09-27 |
Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer
|
Lin, SY;Chang Hsu, Y;Peng, YH;Ke, YY;Lin, WH;Sun, HY;Shiao, HY;Kuo, FM;Chen, PY;Lien, TW;Chen, CH;Chu, CY;Wang, SY;Yeh, KC;Chen, CP;Hsu, TA;Wu, SY;Yeh, TK;Chen, CT;Hsieh, HP |
| 國家衛生研究院 |
2019-07-11 |
Linker optimization and therapeutic evaluation of phosphatidylserine-targeting zinc dipicolylamine-based drug conjugates
|
Liu, YW;Chen, YY;Hsu, CY;Chiu, TY;Liu, KL;Lo, CF;Fang, MY;Huang, YC;Yeh, TK;Pak, KY;Gray, BD;Hsu, TA;Huang, KH;Shih, C;Shia, KS;Chen, CT;Tsou, LK |
| 國家衛生研究院 |
2019-05-28 |
Identification of novel anti-liver cancer small molecules with better therapeutic index than sorafenib via zebrafish drug screening platform
|
Lin, HS;Huang, YL;Wang, YS;Hsiao, E;Hsu, TA;Shiao, HY;Jiaang, WT;Sampurna, BP;Lin, KH;Wu, MS;Lai, GM;Yuh, CH |
| 國家衛生研究院 |
2019-04-01 |
A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus
|
Yeh, TK;Kang, IJ;Hsu, TA;Lee, YC;Lee, CC;Hsu, SJ;Tian, YW;Yang, HY;Chen, CT;Chao, YS;Yueh, A;Chern, JH |
| 國家衛生研究院 |
2018-12 |
Dendritic cell-derived exosomes increase the efficacy of anti-PD-L1 antibody in melanoma model
|
Chao, PK;Hsu, TA |
| 國家衛生研究院 |
2018-12 |
Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer
|
Hung, HC;Yen, WC;Chang, TY;Yen, GJ;Huang, CT;Fang, MY;Lai, YL;Tsai, YR;Chen, CT;Shih, C;Hsu, TA |
| 國家衛生研究院 |
2017-07 |
Targeting tumor associated phosphatidylserine with new zinc dipicolylamine-based drug conjugates
|
Liu, YW;Shia, KS;Wu, CH;Liu, KL;Yeh, YC;Lo, CF;Chen, CT;Chen, YY;Yeh, TK;Chen, WH;Jan, JJ;Huang, YC;Huang, CL;Fang, MY;Gray, BD;Pak, KY;Hsu, TA;Huang, KH;Tsou, LK |
| 國家衛生研究院 |
2017-01 |
A potent, selective, and orally bioavailable HCV NS5A inhibitor for treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazo l-2-yl)pyrrolidine-2-carboxamide
|
Kang, IJ;Hsu, SJ;Yang, HY;Yeh, TK;Lee, CC;Lee, YC;Tian, YW;Song, JS;Hsu, TA;Chao, YS;Yueh, A;Chern, JH |
| 國家衛生研究院 |
2016-07-28 |
Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors
|
Das, A;Adak, AK;Ponnapalli, K;Lin, CH;Hsu, KC;Yang, JM;Hsu, TA;Lin, CC |
| 國家衛生研究院 |
2015-08 |
Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia
|
Hsieh, HP;Hsu, YC;Ke, YY;Shiao, HY;Chang, CW;Lin, WH;Hsu, TA;Yeh, TK;Chen, CT |
| 國家衛生研究院 |
2015-08 |
Optimization of furanopyrimidine-based kinase inhibitors: Identification of a BTK kinase inhibitor for the treatment of B cell lymphoma
|
Wang, WC;Hsu, YC;Shiao, HY;Hung, HC;Kuo, CC;Lee, JC;Hsu, TA;Hsieh, HP |
| 國家衛生研究院 |
2015-08 |
Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors
|
Shiao, HY;Wang, WC;Hsu, YC;Ke, YY;Hsu, TA;Hsieh, HP |
| 國家衛生研究院 |
2015-07-31 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物
|
Hsieh, HP;Coumar, MS;Wu, SY;Hsu, TA;Chao, YS |
| 國家衛生研究院 |
2015-07-22 |
作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物
|
Hsieh, HP;Coumar, MS;Hsu, TA;Lin, WH;Chen, YR;Chao, YS |
| 國立交通大學 |
2014-12-08T15:06:23Z |
ON SOME OPTIMAL SELECTION PROCEDURES FOR WEIBULL POPULATIONS
|
HSU, TA |
顯示項目 1-25 / 83 (共4頁)
1 2 3 4 > >>
每頁顯示[10|25|50]項目
|
